Glenmark Pharmaceuticals Ltd

BSE : GLENMARK14 Feb 2025
Pharmaceuticals
-88.55 (-6.28%)
Lowest Today
Highest Today
Today’s Open
Prev. Close
52 Week High
52 Week Low
To Invest in Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd
Pharmaceuticals
BSE : GLENMARK14 Feb 2025
-88.55 (-6.28%)
1D
1M
6M
1Y
5Y
All

Glenmark Pharmaceuticals Ltd - Share Price & Details

Traded Volume
Market Cap(Cr)
Avg Traded Price
1 Year return
65.94%
Upper Circuit
Lower Circuit
P/E TTM
19.68
P/B Ratio
1.56
Traded Value(Cr)
0.00
EPS TTM
67.15
Book value
Dividend
0.19%

Invest in Glenmark Pharmaceuticals Ltd at ZERO Brokerage for 30 days

Price Performance

-14.21 %
1 Wk
-12.78 %
1 M
-13.73 %
3 M
65.94 %
1 Y
-18.13 %
YTD

Traded Volume Movement

Technical Details

Support 3
1151
Support 2
1231
Support 1
1277
Pivot Point :
1358
Resistance 1
1404
Resistance 2
1484
Resistance 3
1530

Reports

Peer Comparison

Scrip NamePriceDaily ChangeM.Cap (Cr)1 Year Returns %P/E (TTM)PB Ratio
Glenmark Pharmaceuticals Ltd
₹1,321.35(-88.55/-6.28%)
1,321.35-88.5537,286.9365.9419.681.56
Astrazeneca Pharma India Ltd
₹7,096.35(-314.25/-4.24%)
7,096.35-314.2517,740.8832.10105.8426.11
Bliss GVS Pharma Ltd
₹132.25(-5.05/-3.68%)
132.25-5.051,393.5211.6017.181.36
Amrutanjan Health Care Ltd
₹612.45(-25.00/-3.92%)
612.45-25.001,770.63-4.9135.905.95
Abbott India Ltd
₹27,859.05(-511.85/-1.80%)
27,859.05-511.8559,200.48-4.9244.3616.81
Ambalal Sarabhai Enterprises Ltd
₹48.41(-0.97/-1.96%)
48.41-0.97370.98-18.4142.108.23

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 37286.93 crores. It has reported a sales of Rs. 2208.84 crores and a net profit of Rs. 413.8 crores for the quarter ended December 2018. The company management includes Glenn Saldanha, Glenn Saldanha,Cheryl Pinto,V S Mani,B E Saldanha,Rajesh Desai.,Sona Saira Ramasastry,Dipankar Bhattacharjee,V R Iyer (Glenmark Pharmaceuticals Ltd) among others.
Chairman
Glenn Saldanha
Registered office
B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road,Mumbai,Maharashtra,400026
FAX :91-22-40189986
Background
Incorporation Year1977
Face Value₹1
Market Lot1

Latest News

Zydus Passes US FDA Inspection at Ambernath Facility with Zero Observations

Zydus Lifesciences Ltd received the “No Observation” from US Food and Drug Administration in its recently concluded surveillance inspection of its API (Active Pharmaceutical Ingredients) manufacturing facility at Ambernath in Maharashtra. Between February 10-14, 2025, the US FDA conducted an inspection to ensure compliance with US pharmaceutical manufacturing regulations.
16 Feb 2025 | 06:30 PM

Oscar Global Q3 results 2025 on 16 Feb, 2025: loss at  ₹0.08Cr

Oscar Global's Q3 2025 results showed a topline decrease of 0%, with a reported loss of ₹0.08cr, compared to a profit of ₹0.04cr last year, amidst challenging market conditions, with operating income down 140% quarter-over-quarter and 200% year-over-year, and EPS at ₹-0.23, raising concerns about the company's financial health.
16 Feb 2025 | 06:17 PM

Elgi Rubber Company Q3 Results 2025 on 16 Feb, 2025

Elgi Rubber Company Q3 Results 2025: Elgi Rubber Company declared their Q3 results on 13 Feb, 2025, reporting a significant decline in their financial performance. The topline decreased by 3.41% year-over-year, with the company facing a loss of  ₹3.5 crore, representing an increase of 82.29% compared to the previous year. Revenue stood at  ₹91.48 crore.
16 Feb 2025 | 06:13 PM

Tamil Nadu Newsprint & Papers Q3 results 2025 on 16 Feb, 2025

Tamil Nadu Newsprint & Papers Q3 Results 2025: Tamil Nadu Newsprint & Papers declared their Q3 results on 13 Feb, 2025. The topline decreased by 9.28% and the loss came at ₹42.89cr. It is noteworthy that Tamil Nadu Newsprint & Papers had declared a profit of  ₹16.2cr in the previous fiscal year for the same period. However, as compared to the previous quarter, the revenue grew by 23.09%.
16 Feb 2025 | 06:11 PM

M M T C Q3 Results 2025 on 16 Feb, 2025: profit falls by 93.43% YOY

M M T C Q3 Results 2025:M M T C declared their Q3 results on 13 Feb, 2025. The topline decreased by 65.75% & the profit decreased by 93.43% YoY. Profit stood at  ₹3.66 crore while revenue was at  ₹0.25 crore. As compared to the previous quarter, the revenue declined by 83.97% and the profit decreased by 92.38%.
16 Feb 2025 | 06:10 PM

How to buy Glenmark Pharmaceuticals Ltd shares on nse?

To buy Glenmark Pharmaceuticals Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Glenmark Pharmaceuticals Ltd share price today?

The Glenmark Pharmaceuticals Ltd shares price on nse is Rs.1321.35 today.

What is the market cap of Glenmark Pharmaceuticals Ltd shares on BSE ?

The company has a market capitalization of Rs.37286.93Cr

What is the PE & PB ratio of Glenmark Pharmaceuticals Ltd shares ?

PE is 19.68 and PB is 1.56

What is the 52 Week High and Low of Glenmark Pharmaceuticals Ltd shares?

Glenmark Pharmaceuticals Ltd stock price high: Rs.1830.05 Glenmark Pharmaceuticals Ltd stock price low: Rs.766.65

How has the GLENMARK share price performed in the past year?

In April 2022, the huge pharmaceutical GLENMARK’s share price was in the region of Rs. 478. By June, it had dipped to the late 300 levels and never significantly went up till November. Highs were felt in December, and February 2023, and now the stock is at the 448 level. 

Does GLENMARK pay dividends to its shareholders?

GLENMARK has a consistent track record of paying dividends to its loyal shareholders. In the recent past, the company has paid only final dividends, but interim dividends have been paid in the past as well. 

What is the dividend yield of GLENMARK?

The dividend yield of GLENMARK is 0.56% (March 2022). 

How does GLENMARK compare to its competitors in terms of share price?

Compared to popular competitors of GLENMARK, like Sun Pharma, Dr Reddy’s Labs, CIPLA, Torrent Pharma, Abbott India and others, the company’s share price is low at the moment (March 2023). Most of these companies have their share prices in the thousands, or late hundreds, whereas GLENMARK seems firmly poised on the mid-hundred mark. 

What is the company's debt-to-equity ratio?

The company’s debt-to-equity ratio is 0.22. 

What is the company's revenue and net income?

The revenue of GLENMARK is Rs. 3,463 crores (Q3 FY 2022-23)  and the net income is Rs. 291 crores (December 2022). 

How long has GLENMARK been in business?

GLENMARK started its foray into the pharmaceutical business with “Candid Cream”, a key dermatological drug, even in use now. The company started its business in 1977, headed by its Founder Emeritus, the late Gracias Saldanha. 

What is the company's history of share price performance?

The share price of GLENMARK has been somewhat stable in the last 4-5 years, not showing much volatility as other pharma stocks have. In 2018, the share was in the region of the 500 mark, peaking at nearly 700 in 2019. Then, with a gradual and slow downward movement, it dipped to the region of 199 in 2020, only to slowly rise to 662 in 2021. Since then, it has been in the range of between 400-500 and is steady now. 

Click here to see your activities